COMPANY

Impulse Dynamics

HQ: Marlton, NJ source · impulse-dynamics.com ↗

Keywords: heart failure cardiovascular Congestive Heart Failure Diastolic Heart Failure NYHA Class III Heart Failure Chronic Heart Disease Heart Failure With Preserved Ejection Fraction Heart Failure With Mid Range Ejection Fraction Heart Failure With Moderately Reduced Ejection Fraction Heart Failure With Reduced Ejection Fraction Implantable Defibrillator User CCM Therapy Non-ischemic Cardiomyopathy Ischemic Cardiomyopathy Sudden Cardiac Arrest Cardiac Arrhythmias Ventricular Tachycardia Ventricular Fibrillation Heart Failure and Reduced Ejection Fraction Evaluate the Safety and Useability of the ODOCOR II Intra-cardiac Lead NYHA Class IV Heart Failure OPTIMIZER Smart System Optimizer System Cardiac Contractility Modulation Optimizer SMART ODOCOR II CCM LEADS Optimizer Smart System with 2-leads

Location: Marlton, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

$136.0MRaised (2 yrs)13Trials (company is sponsor)

Raises and deals from press releases

Raise Undisclosed round · $158M · announced Dec 10, 2025 Company release ↗
Source quote
- Dec 10, 2025 · Company release ↗
  “Impulse Dynamics Completes $158M Financing Round”

Raises announced in these releases: $158M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Dec 10, 2025 Raise Undisclosed round · $158M source ↗
Nov 18, 2025 Trial start —: Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure source ↗
Nov 1, 2025 Trial start —: CCM OPEN HF Registry source ↗
Jun 25, 2025 Raise Private equity round: $136M (total, as published), announced Jun 25, 2025. Source: company's own press page. source ↗
Feb 1, 2025 Trial start —: CCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF) source ↗
May 17, 2023 Trial start Not phased (device or behavioral study): Assessment of Combined CCM and ICD Device in HFrEF source ↗
Feb 3, 2022 Trial start Not phased (device or behavioral study): Assessment of CCM in HF With Higher Ejection Fraction source ↗
Mar 1, 2021 Trial start —: Optimizer System With ODOCOR II CCM™ Leads source ↗
Jan 21, 2020 Trial start —: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy source ↗
May 1, 2018 Trial start Not phased (device or behavioral study): CCM in Heart Failure With Preserved Ejection Fraction source ↗
Oct 23, 2017 Trial start Not phased (device or behavioral study): Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System source ↗
Jul 1, 2017 Trial start Not phased (device or behavioral study): Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System source ↗
2014-02 Trial start Not phased (device or behavioral study): Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure source ↗
2011-01 Trial start Not phased (device or behavioral study): Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C source ↗
2005-02 Trial start Not phased (device or behavioral study): Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5 source ↗

Upcoming milestones

2027-06 (ESTIMATED) · · CCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF) · NCT06580392
2028-07 (ESTIMATED) · · Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy · NCT03970343
Feb 1, 2029 (ESTIMATED) · Not phased · Assessment of CCM in HF With Higher Ejection Fraction · NCT05064709
2030-10 (ESTIMATED) · · Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure · NCT07209098
Aug 15, 2035 (ESTIMATED) · · CCM OPEN HF Registry · NCT07112924

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $136.0M. Last 2 years.

Jun 25, 2025 Private equity round: $136M (total, as published), announced Jun 25, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 13

Record	Title	Phase	Status	Start	Primary completion
NCT05064709	Assessment of CCM in HF With Higher Ejection Fraction	Not phased (device or behavioral study)	Recruiting	Feb 3, 2022	Feb 1, 2029 (estimated)
NCT05855135	Assessment of Combined CCM and ICD Device in HFrEF	Not phased (device or behavioral study)	Active, not recruiting	May 17, 2023	2026-05 (estimated)
NCT07112924	CCM OPEN HF Registry	Not listed	Recruiting	Nov 1, 2025	Aug 15, 2035 (estimated)
NCT07209098	Propensity-Matched Study of Cardiac Contractility Modulation Therapy in Heart Failure	Not listed	Recruiting	Nov 18, 2025	2030-10 (estimated)
NCT03970343	Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy	Not listed	Active, not recruiting	Jan 21, 2020	2028-07 (estimated)
NCT06580392	CCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF)	Not listed	Recruiting	Feb 1, 2025	2027-06 (estimated)
NCT03240237	CCM in Heart Failure With Preserved Ejection Fraction	Not phased (device or behavioral study)	Completed	May 1, 2018	Jul 25, 2023 (actual)
NCT04755569	Optimizer System With ODOCOR II CCM™ Leads	Not listed	Unknown status (ClinicalTrials.gov)	Mar 1, 2021	Dec 31, 2024 (estimated)
NCT03102437	Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System	Not phased (device or behavioral study)	Terminated	Jul 1, 2017	Dec 16, 2019 (actual)
NCT01381172	Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C	Not phased (device or behavioral study)	Completed	2011-01	Mar 19, 2019 (actual)
NCT02857309	Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure	Not phased (device or behavioral study)	Terminated	2014-02	Feb 15, 2018 (actual)
NCT00112125	Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5	Not phased (device or behavioral study)	Completed	2005-02	Mar 19, 2019 (actual)
NCT03339310	Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System	Not phased (device or behavioral study)	Completed	Oct 23, 2017	Oct 30, 2019 (actual)